Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

计划入组 62 人 · 首次发布于 2015 年 2 月 10 日

Olfactory and Brain Stimulations in Treatment-resistant Depression

计划入组 80 人 · 首次发布于 2022 年 12 月 22 日

Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression

计划入组 119 人 · 首次发布于 2018 年 10 月 10 日

Treatment-Resistant Depression(Blue Oak)

Esketamine(Spravato)

C₁₃H₁₆ClNO · Rx

Botulism Treatment

IT INTELLIGENT TREATMENT LLC

United States

BIO-CANCER TREATMENT INTERNATIONAL LIMITED

Hong Kong, China

SPONDYLOARTHRITIS RESEARCH AND TREATMENT NETWORK

United States

Oxford Health Launches Groundbreaking Psilocybin Trial for Treatment-Resistant Depression

SPRAVATO Receives FDA Approval as First Monotherapy for Treatment-Resistant Depression

FDA Approves Spravato (Esketamine) Nasal Spray as Standalone Treatment for Treatment-Resistant Depression